Lexaria Bioscience Corp Stock Analysis

Lexaria Stock Analysis Notes

The book value of the company was now reported as 0.22. The company recorded a loss per share of 0.57. Lexaria Bioscience Corp last dividend was issued on the 12th of January 2021. The entity had 1:30 split on the 12th of January 2021. Lexaria Bioscience Corp. operates as a biotechnology company. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. Lexaria Bioscience is traded on NASDAQ Exchange in the United States. To find out more about Lexaria Bioscience Corp contact Christopher Bunka at 250 765 6424 or learn more at https://lexariabioscience.com.

Lexaria Bioscience Corp Investment Alerts

Lexaria Largest EPS Surprises

View All Earnings Estimates

Lexaria Stock Institutional Investors

Note, although Lexaria Bioscience's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Lexaria Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.49 M.

Lexaria Profitablity

Management Efficiency

Lexaria Bioscience Corp has return on total asset (ROA) of (0.8296) % which means that it has lost $0.8296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5523) %, meaning that it created substantial loss on money invested by shareholders. Lexaria Bioscience's management efficiency ratios could be used to measure how well Lexaria Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.14 in 2026, whereas Return On Tangible Assets are likely to drop (0.55) in 2026. At this time, Lexaria Bioscience's Other Current Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 60.5 K in 2026, whereas Total Assets are likely to drop slightly above 4.3 M in 2026.

Technical Drivers

As of the 17th of February 2026, Lexaria Bioscience secures the Risk Adjusted Performance of (0.06), mean deviation of 5.14, and Standard Deviation of 7.35. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lexaria Bioscience Corp, as well as the relationship between them.

Lexaria Bioscience Corp Price Movement Analysis

Lexaria Bioscience Corp Insider Trading Activities

Lexaria Bioscience Outstanding Bonds

Lexaria Bioscience Predictive Daily Indicators

Lexaria Bioscience Forecast Models

Lexaria Bioscience's time-series forecasting models are one of many Lexaria Bioscience's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lexaria Bioscience's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Lexaria Bioscience Bond Ratings

Lexaria Bioscience Corp financial ratings play a critical role in determining how much Lexaria Bioscience have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Lexaria Bioscience's borrowing costs.

Lexaria Bioscience Corp Debt to Cash Allocation

Lexaria Bioscience Corp currently holds 109.32 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Lexaria Bioscience Corp has a current ratio of 39.29, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Lexaria Bioscience's use of debt, we should always consider it together with its cash and equity.

Lexaria Bioscience Total Assets Over Time

Lexaria Bioscience Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Lexaria Bioscience uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Lexaria Bioscience Debt Ratio

19.0

It appears most of the Lexaria Bioscience's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Lexaria Bioscience's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Lexaria Bioscience, which in turn will lower the firm's financial flexibility.

Lexaria Bioscience Corporate Bonds Issued

Lexaria Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Lexaria Bioscience prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Lexaria shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Lexaria Bioscience. By using and applying Lexaria Stock analysis, traders can create a robust methodology for identifying Lexaria entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Lexaria analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Lexaria analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Lexaria Bioscience Corp stock analysis indicators help investors evaluate how Lexaria Bioscience stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Lexaria Bioscience shares will generate the highest return on investment. By understating and applying Lexaria Bioscience stock analysis, traders can identify Lexaria Bioscience position entry and exit signals to maximize returns.

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.